These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36344074)

  • 1. Update on Clinical Outcomes of Highly Effective Modulator Therapy.
    Gifford AH; Taylor-Cousar JL; Davies JC; McNally P
    Clin Chest Med; 2022 Dec; 43(4):677-695. PubMed ID: 36344074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation.
    Caverly LJ; Riquelme SA; Hisert KB
    Clin Chest Med; 2022 Dec; 43(4):647-665. PubMed ID: 36344072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges in the use of highly effective modulator treatment for cystic fibrosis.
    Ramos KJ; Pilewski JM; Taylor-Cousar JL
    J Cyst Fibros; 2021 May; 20(3):381-387. PubMed ID: 33531206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy.
    Lahiri T; Sullivan JS
    Pediatr Pulmonol; 2022 Feb; 57 Suppl 1():S60-S74. PubMed ID: 34473419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivering a New Future for People With Cystic Fibrosis.
    Burgener EB; Cornfield DN
    Pediatrics; 2023 Oct; 152(4):. PubMed ID: 37671451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced Cystic Fibrosis Lung Disease and Lung Transplantation in the Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
    O'Carroll M
    Semin Respir Crit Care Med; 2023 Apr; 44(2):260-268. PubMed ID: 36893762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystic fibrosis transmembrane conductance receptor modulator therapy in cystic fibrosis, an update.
    Egan ME
    Curr Opin Pediatr; 2020 Jun; 32(3):384-388. PubMed ID: 32374578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung Inflammatory Genes in Cystic Fibrosis and Their Relevance to Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapies.
    Carbone A; Vitullo P; Di Gioia S; Conese M
    Genes (Basel); 2023 Oct; 14(10):. PubMed ID: 37895314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
    Flume PA; Biner RF; Downey DG; Brown C; Jain M; Fischer R; De Boeck K; Sawicki GS; Chang P; Paz-Diaz H; Rubin JL; Yang Y; Hu X; Pasta DJ; Millar SJ; Campbell D; Wang X; Ahluwalia N; Owen CA; Wainwright CE;
    Lancet Respir Med; 2021 Jul; 9(7):733-746. PubMed ID: 33581080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on Cystic Fibrosis in Pediatric Patients.
    Lusman SS
    Curr Gastroenterol Rep; 2023 Nov; 25(11):308-315. PubMed ID: 37653358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Airway clearance after highly effective CFTR modulators: Normalizing life and reducing treatment burden.
    Goetz DM; Frederick CK; Perez G; Borowitz D
    Pediatr Pulmonol; 2023 Aug; 58(8):2375-2380. PubMed ID: 37232336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy.
    Saiman L
    Pediatr Pulmonol; 2019 Nov; 54 Suppl 3():S18-S26. PubMed ID: 31715086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
    Mayer-Hamblett N; Boyle M; VanDevanter D
    Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis.
    Wu HX; Zhu M; Xiong XF; Wei J; Zhuo KQ; Cheng DY
    Adv Ther; 2019 Feb; 36(2):451-461. PubMed ID: 30554331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on new and emerging therapies for cystic fibrosis.
    Hudock KM; Clancy JP
    Expert Opin Emerg Drugs; 2017 Dec; 22(4):331-346. PubMed ID: 29264936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
    Cuyx S; De Boeck K
    Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of modulator therapies on endocrine complications in adults with cystic fibrosis: a narrative review.
    Kumar S; Soldatos G; Teede HJ; Pallin M
    Med J Aust; 2023 Nov; 219(10):496-502. PubMed ID: 37839059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies.
    Desai M; Hine C; Whitehouse JL; Brownlee K; Charman SC; Nagakumar P
    Respir Med; 2022 Aug; 199():106878. PubMed ID: 35633605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.